Article
Psychiatry
Mukesh Chand Daderwal, Vanteemar S. Sreeraj, Satish Suhas, Naren P. Rao, Ganesan Venkatasubramanian
Summary: Cognitive deficit is a core feature of schizophrenia and is associated with poor functional outcomes. This study evaluated the validity and sensitivity of MoCA and DSST in identifying cognitive deficits in schizophrenia. The results showed that combining MoCA and DSST is a sensitive and quick method for screening neurocognitive deficits in schizophrenia.
PSYCHIATRY RESEARCH
(2022)
Review
Psychiatry
Ahmad Mayeli, Kevin J. Clancy, Susan Sonnenschein, Deepak K. Sarpal, Fabio Ferrarelli
Summary: Cognitive dysfunction is a key characteristic of schizophrenia, which has negative effects on patients' daily functioning and overall clinical outcomes. However, research has shown that cognitive deficits can be present several years before the onset of psychosis. Most treatment interventions for cognitive dysfunction in schizophrenia have focused on chronic patients, neglecting those at high risk or in the early stages of the disease. This article provides a review of cognitive interventions in schizophrenia patients, with a specific focus on preemptive interventions for at-risk/early course individuals, and discusses current challenges and suggestions for future improvements.
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
Shujuan Pan, Wei Feng, Yanli Li, Junchao Huang, Song Chen, Yimin Cui, Baopeng Tian, Shuping Tan, Zhiren Wang, Shangwu Yao, Joshua Chiappelli, Peter Kochunov, Shuo Chen, Fude Yang, Chiang-Shan R. Li, Li Tian, Yunlong Tan, L. Elliot Hong
Summary: The study found elevated levels of miR-195 and decreased levels of BDNF mRNA and protein in patients with schizophrenia compared to healthy controls. There was a significant negative correlation between miR-195 and BDNF protein levels, which in turn were significantly associated with overall cognitive performance as well as specific cognitive domains. These findings suggest that miR-195 may play a role in regulating cognitive impairments in schizophrenia through its influence on BDNF protein expression, highlighting the potential for micro-RNA based strategies in treating cognitive deficits in schizophrenia.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Psychiatry
Alexander Panickacheril John, Thynn Mya, Darren Haywood
Summary: This study found that patients with schizophrenia and dysglycaemia, especially those with T2DM, have more pronounced cognitive deficits compared to patients with schizophrenia with normal blood sugar.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Article
Clinical Neurology
Farideh Sinichi, Farhad Farid Hosseini, Mohammadreza Fayyazi-Bordbar, Mohaddeseh Sinichi, Jamshid Jamali, Amirhooshang Mohammadpour
Summary: A study on 52 patients with chronic schizophrenia found that Pentoxifylline, as an adjunctive therapy, can improve cognitive deficits and psychotic symptoms.
JOURNAL OF PSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Yushen Ding, Qing Tian, Wenpeng Hou, Zhenzhu Chen, Zhen Mao, Qijing Bo, Fang Dong, Chuanyue Wang
Summary: This study investigated the relationship between sensory gating and cognitive function in schizophrenia patients. It found impairments in both sensory gating and cognitive function, with the PSSPPI measure at 60 ms showing significant associations with clinical symptoms and cognitive performance.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Psychiatry
Xing-Jie Peng, Gang-Rui Hei, Ye Yang, Chen-Chen Liu, Jing-Mei Xiao, Yu-Jun Long, Jing Huang, Jing-Ping Zhao, Ren-Rong Wu
Summary: This study revealed a high prevalence of cognitive deficits in first-episode drug-naive schizophrenia patients compared to the general population. The relationship between cognitive deficits and negative symptoms and general pathology symptoms showed negative correlations, while no correlation was found between cognitive deficits and positive symptoms.
FRONTIERS IN PSYCHIATRY
(2021)
Review
Cardiac & Cardiovascular Systems
Heinz Drexel, Basil S. Lewis, Giuseppe M. C. Rosano, Christoph H. Saely, Gerda Tautermann, Kurt Huber, Joern F. Dopheide, Juan Carlos Kaski, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Thomas A. Schmidt, AnneGrete Semb, Juan Tamargo, Sven Wassmann, Keld Per Kjeldsen, Stefan Agewall, Stuart J. Pocock
Summary: This review article discusses the important issues that data safety monitoring boards face when considering early termination of a trial, focusing on efficacy, futility, and harm reasons for stopping trials. It also covers statistical essentials and regulatory aspects, with examples from lipid and antithrombotic trials, to provide insights into the decision-making process for stopping a randomized clinical trial.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2021)
Article
Medicine, General & Internal
Pinhong Chen, Dongmei Wang, Meihong Xiu, Dachun Chen, Blake Lackey, Hanjing E. Wu, Lubin Wang, Xiangyang Zhang
Summary: Recent literature has focused on impaired iron homeostasis in the pathophysiology of schizophrenia. This study investigated the correlation between transferrin gene polymorphism and cognitive deficits and clinical symptoms in schizophrenia. The results suggest that the rs3811655 polymorphism is related to cognitive performance, negative symptoms, and total psychiatric symptoms in patients with schizophrenia.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Psychiatry
Stanislav V. Ivanov, Anatoly B. Smulevich, Evgeniya I. Voronova, Kausar K. Yakhin, Tangyul Z. Beybalaeva, Alena A. Katok
Summary: The study evaluated the initial effects of cariprazine in schizophrenia patients with predominantly negative symptoms, showing improvement in 75% of patients within 28 days of treatment. Significant reductions in negative symptoms were observed, suggesting an early effect of cariprazine on negative symptoms in some patients.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Geriatrics & Gerontology
Mi Yang, Ying Cui, Mei Xue, Mattew T. Forster, Xiaoe Lang, Meihong Xiu, Zezhi Li, Xiangyang Zhang
Summary: This study reveals a sex difference in the language deficits of schizophrenia patients and demonstrates sexual dimorphism in the contribution of FOXP2, BMI, and their interaction to cognitive deficits in patients with schizophrenia.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Elia Vila, Raquel Pinacho, Roger Prades, Teresa Tarrago, Elena Castro, Eva Munarriz-Cuezva, J. Javier Meana, Ania Eugui-Anta, Monica Roldan, America Vera-Montecinos, Belen Ramos
Summary: Cognitive impairment is a core feature of schizophrenia. Prolyl Oligopeptidase (POP) inhibition is an emerging strategy for compensating cognitive deficits in hypoglutamatergic states such as schizophrenia. The mitochondrial and nuclear protein Prohibitin 2 (PHB2) could be dysregulated in schizophrenia, and its link to N-methyl-D-aspartate receptor (NMDAR) activity and cognitive deficits is still unknown. This study found that PHB2 levels increased in the dorsolateral prefrontal cortex of chronic schizophrenia cases, and were associated with cognitive impairments. NMDAR antagonists also increased PHB2 levels in mice and rat astrocytes and neurons, and IPR19 restored PHB2 levels in acute NMDAR inhibition.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Simona Cintoli, Camilla Elefante, Claudia Radicchi, Giulio Emilio Brancati, Silvia Bacciardi, Joyce Bonaccorsi, Gabriele Siciliano, Icro Maremmani, Giulio Perugi, Gloria Tognoni
Summary: This study examines the influence of affective temperament on the motivation of individuals with mild cognitive impairment (MCI) and subjective cognitive decline (SCD) to participate in clinical trials. The findings suggest that temperamental features can impact the willingness of patients with MCI and SCD to participate in clinical trials, particularly pharmacological studies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Ronald C. Petersen, Paul S. Aisen, J. Scott Andrews, Alireza Atri, Brandy R. Matthews, Dorene M. Rentz, Eric R. Siemers, Christopher J. Weber, Maria C. Carrillo
Summary: Alzheimer's disease (AD) clinical trials are designed to detect the impact of therapeutic intervention, and there has been considerable discussion on defining a clinically meaningful change in treatment outcomes. The complexity of AD pathology and the need for early intervention make it crucial to assess meaningful change over the course of clinical trials. The Alzheimer's Association has convened experts to discuss key considerations for interpreting data and re-evaluating the expectations of therapeutic interventions in AD.
ALZHEIMERS & DEMENTIA
(2023)
Article
Biochemistry & Molecular Biology
Jiaxin Li, Deyang Li, Junru Guo, Dongmei Wang, Xiangyang Zhang
Summary: Patients with early-onset schizophrenia have more severe negative symptoms and cognitive deficits. Oxidative stress is believed to be involved in cognitive impairment in schizophrenia. Total antioxidant capacity (TAOC) is an important indicator of oxidative stress. However, the relationship between age of onset, TAOC, and cognitive performance in schizophrenia has not been explored.
